Tagged with UK

Medtech Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. He calls for healthcare to be given a new prescription. But, will the private sector write it?   The UK’s National Health Service has crippling sustainability challenges.   With many firms in the midst of or preparing for annual strategic planning sessions, it feels appropriate…

BIOTECH This week the NHS becomes the first in the world to routinely offer access to breakthrough genomic medicine. Today (1st October 2018) marks a huge stride in ‘precision medicine’ in the UK as the NHS begins to offer gene therapies tailored to individual patients. Hospitals across England have connected to specialist…

UK The UK country managers of some of the biggest global pharma companies explain what it takes to manage in the UK market.   Erik Nordkamp, Pfizer Erik Nordkamp, the Dutch national serving as managing director of Pfizer UK and the newly-appointed president of the ABPI, likens managing a UK affiliate…

UK For French mid-cap Ipsen, the UK is one of three global hubs, with manufacturing in Wales, large-scale R&D activities near Oxford as well as UK Commercial Operations and global functions including HR, Tech Ops and Commercial Operations in Slough, near London. With ten percent annual growth to reach GBP 80…

UK Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of Amgen company culture.   Everyone tells you how complicated the UK market is and that is true – it’s one…

UK The Top 15 pharmaceutical companies in the UK in the year up to March 2018 according to IQVIA data, ranked by market share. Pfizer leads the way with a whopping 8.2% market share, followed by Novartis with 6% and GSK with 5.3%

UK There is much debate surrounding the potential impact on the UK’s life sciences industry of the country’s decision to leave the European Union. Here, IQVIA analysis posits ‘upside’ and ‘downside’ Brexit scenarios on pharmaceutical market sales and growth in the UK in comparison to a theoretical ‘No Brexit’ scenario. Different…

R&D In my career, I’ve held senior roles in both the biopharma and diagnostics sectors. Working across different cost structures, different business issues, and different regulatory systems in different parts of the world. I was once challenged as a new CEO in diagnostics by a pharma analyst to explain why I…

UK A spinout from the Roslin Institute that created Dolly the Sheep, Roslin CT is a cell and gene therapy CDMO, with a unique positioning in the field today. Its CEO, Janet Downie, presents the company’s expansion plans and talks about new areas worth pursuing as well as the advantages of…

UK Jonny Ohlson, founder & CEO of Touchlight, discusses the genetic medicine revolution and the role of Touchlight in disrupting the field with its revolutionary DNA technology. You founded Touchlight Genetics in 2007. What was the rationale, and could you please introduce what is so unique about your company? The advent…

Brexit Despite a myriad of uncertainties around its decision to leave the European Union, the UK still stands as one of the world’s premier life science investment destinations. With heavyweight medical science infrastructure and a well-earned reputation for elite-level innovation, the key industry stakeholders featured in our UK report, explore how…

Cannabis Founded in 1998, GW Pharmaceuticals is a true pioneer in cannabinoid medicines and the only pharmaceutical company with a license to cultivate cannabis in the UK. “While people were wary of cannabis, they became very aware that it was treating patients with severe conditions, where other medicines had either failed…